Immunohistochemical expression of TFF1 is a marker of poor prognosis in retinoblastoma.

Autor: Aschero R; Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina.; National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.; SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain.; Institut de Recerca Sant Joan de Deu, Barcelona, Spain., Ganiewich D; Instituto de Investigaciones en Medicina Traslacional - Universidad Austral, Buenos Aires, Argentina., Lamas G; Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Restrepo-Perdomo CA; Pathology Service, Hospital Sant Joan de Deu, Barcelona, Spain., Ottaviani D; SIREDO Center, Institut Curie and University Paris Cité, Paris, France., Zugbi S; National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.; Unidad de tratamientos innovadores, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Camarero S; Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Néspoli E; Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Vilanova MC; SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain.; Institut de Recerca Sant Joan de Deu, Barcelona, Spain., Perez-Jaume S; SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain.; Institut de Recerca Sant Joan de Deu, Barcelona, Spain., Pascual-Pasto G; SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain.; Institut de Recerca Sant Joan de Deu, Barcelona, Spain., Sampor C; Hematology-Oncology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Grigorovski N; Department of Pediatric Oncology, Clinical Division, National Institute of Cancer, Rio de Janeiro, Brazil., Salas B; Department of Pediatric Oncology, Hospital del Niño Manuel A. Villarroel, Cochabamba, Bolivia., Suñol M; Pathology Service, Hospital Sant Joan de Deu, Barcelona, Spain., Carcaboso AM; SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain.; Institut de Recerca Sant Joan de Deu, Barcelona, Spain., Mora J; SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain.; Institut de Recerca Sant Joan de Deu, Barcelona, Spain., de Dávila MTG; Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Doz F; SIREDO Center, Institut Curie and University Paris Cité, Paris, France., Radvanyi F; SIREDO Center, Institut Curie and University Paris Cité, Paris, France., Abramson DH; Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA., Llera AS; National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.; Instituto de Investigaciones en Medicina Traslacional - Universidad Austral, Buenos Aires, Argentina.; Laboratory of Molecular and Cellular Therapy, Instituto Leloir-Instituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Buenos Aires, Argentina., Schaiquevich PS; National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.; Unidad de tratamientos innovadores, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Lubieniecki F; Pathology Service, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Chantada GL; National Scientific and Technical Research Council, CONICET, Buenos Aires, Argentina.; SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain.; Institut de Recerca Sant Joan de Deu, Barcelona, Spain.; Hematology Oncology Service, Hospital Pereyra Rossell, Montevideo, Uruguay.
Jazyk: angličtina
Zdroj: Pediatric blood & cancer [Pediatr Blood Cancer] 2024 Jan; Vol. 71 (1), pp. e30717. Date of Electronic Publication: 2023 Oct 09.
DOI: 10.1002/pbc.30717
Abstrakt: Introduction: The risk of relapse in retinoblastoma is currently determined by the presence of high-risk histopathologic factors in the enucleated eye. However, the probability of developing metastatic disease is heterogeneous among these patients. Evaluating a biological marker to identify high-risk patients could be useful in clinical setting. This study aims to evaluate whether the expression of TFF1, a surrogate for subtype 2 retinoblastoma, is a prognostic marker for relapse and death.
Methods: This multicenter cohort study included 273 patients, 48 of whom had extraocular disease. Immunohistochemical staining were performed for CRX, ARR3, TFF1, and Ki67. Tumors were classified as histological subtype 1 (HS1) if they had low or no expression of TFF1 (quick score (QS) ≤ 50) and as histological subtype 2 (HS2) if they expressed TFF1 diffusely (QS > 50). We studied the association between HS classification and outcome.
Results: Of 273 patients, 35.9% were classified as HS1, 59.3% as HS2 and 4.8% were not evaluable. In multivariate analysis, patients with HS2 tumors had a higher probability of relapse and death than those with HS1 (p < .0001 and p = .00020, respectively). We identified a higher-risk subgroup among HS2 tumors, presenting non-mutually exclusive expression of ARR3 and TFF1 and had an increased risk of relapse and death compared with tumors that displayed mutually exclusive expression (p = .012 and p = .027, respectively).
Conclusions: Expression of TFF1, especially when it is not-mutually exclusive with ARR3, is an independent significant marker of poor outcome in retinoblastoma.
(© 2023 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: